查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
胰島素的全球市場 - 產業分析，規模，佔有率，成長，趨勢，預測(2022年～2031年)
市場調查報告書
商品編碼
1110387

胰島素的全球市場 - 產業分析，規模，佔有率，成長，趨勢，預測(2022年～2031年)

Insulin Market (Mode of Action: Rapid-acting, Short-acting, Intermediate-acting, Premixed, and Long-acting; and Source: Modern Insulin and Human Insulin) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2022-2031
出版日期: | 出版商: Transparency Market Research | 英文 160 Pages | 商品交期: 2-10個工作天內

價格

本報告提供全球胰島素市場相關調查分析，市場趨勢，市場區隔分析，地區分析，企業簡介等資訊。

目錄

第1章 序文

第2章 前提條件與調查手法

第3章 摘要整理:全球胰島素市場

第4章 市場概要

  • 簡介
    • 定義
    • 產業的演進/發展
  • 概要
  • 市場動態
    • 促進因素
    • 阻礙因素
    • 機會
  • 全球胰島素市場分析與預測(2017年～2031年)

第5章 主要洞察

  • 法規情境:各地區/世界
  • 主要的合併和收購
  • 技術進步
  • COVID-19大流行對產業的影響

第6章 全球胰島素市場分析與預測:各作用機制

  • 簡介和定義
  • 主要的調查結果/發展
  • 市場價值預測(2017年～2031年):各作用機制
    • 超速效型
    • 速效型
    • 中間型
    • 混合型
    • 時效型
  • 市場魅力分析:各作用機制

第7章 全球胰島素市場分析與預測:各來源

  • 簡介和定義
  • 主要的調查結果/發展
  • 市場價值預測(2017年～2031年):各來源
    • 胰島素類似物
    • 胰島素注射液
  • 市場魅力分析:各來源

第8章 全球胰島素市場分析與預測:各地區

  • 主要的調查結果
  • 市場價值預測:各地區
    • 北美
    • 歐洲
    • 亞太地區
    • 南美
    • 中東、非洲
  • 市場魅力分析:各地區

第9章 北美的胰島素市場分析與預測

  • 簡介
    • 主要的調查結果
  • 市場價值預測(2017年～2031年):各作用機制
    • 超速效型
    • 速效型
    • 中間型
    • 混合型
    • 時效型
  • 市場價值預測(2017年～2031年):各來源
    • 胰島素類似物
    • 胰島素注射液
  • 市場價值預測(2017年～2031年):各國
    • 美國
    • 加拿大
  • 市場魅力分析
    • 各作用機制
    • 各來源
    • 各國

第10章 歐洲的胰島素市場分析與預測

第11章 亞太地區的胰島素市場分析與預測

第12章 南美的胰島素市場分析與預測

第13章 中東、非洲的胰島素市場分析與預測

第14章 競爭情形

  • 市場企業 - 競爭矩陣(各階層、企業規模)
  • 市場佔有率分析(2021年):各企業
  • 企業簡介
    • Shanghai Fosun Pharmaceutical Co., Ltd.
    • Tonghua Dongbao
    • Eli Lilly and Company
    • Sanofi
    • Novo Nordisk A/S
    • Julphar
    • Biocon Ltd.
    • Becton, Dickinson and Company
    • Ypsomed AG
    • Biodel Inc.
    • B. Braun Melsungen AG
Product Code: TMRGL259

The report provides revenue of the global insulin market for the period 2017-2031, considering 2021 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global insulin market from 2022 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the insulin market.

The report delves into the competitive landscape of the global insulin market. Key players operating in the global insulin market have been identified and each one of these has been profiled, in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are attributes of players in the global insulin market profiled in this report.

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Insulin Market

4. Market Overview

  • 4.1. Introduction
    • 4.1.1. Definition
    • 4.1.2. Industry Evolution / Developments
  • 4.2. Overview
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
    • 4.3.2. Restraints
    • 4.3.3. Opportunities
  • 4.4. Global Insulin Market Analysis and Forecast, 2017-2031

5. Key Insights

  • 5.1. Regulatory Scenario, by Region/globally
  • 5.2. Key Mergers & Acquisitions
  • 5.3. Technological Advancements
  • 5.4. COVID-19 Pandemics Impact on Industry

6. Global Insulin Market Analysis and Forecast, by Mode of Action

  • 6.1. Introduction & Definition
  • 6.2. Key Findings / Developments
  • 6.3. Market Value Forecast, by Mode of Action, 2017-2031
    • 6.3.1. Rapid-acting
    • 6.3.2. Short-acting
    • 6.3.3. Intermediate-acting
    • 6.3.4. Premixed
    • 6.3.5. Long-acting
  • 6.4. Market Attractiveness Analysis, by Mode of Action

7. Global Insulin market Analysis and Forecast, by Source

  • 7.1. Introduction & Definition
  • 7.2. Key Findings / Developments
  • 7.3. Market Value Forecast, by Source, 2017-2031
    • 7.3.1. Modern Insulin
    • 7.3.2. Human Insulin
  • 7.4. Market Attractiveness Analysis, by Source

8. Global Insulin market Analysis and Forecast, by Region

  • 8.1. Key Findings
  • 8.2. Market Value Forecast, by Region
    • 8.2.1. North America
    • 8.2.2. Europe
    • 8.2.3. Asia Pacific
    • 8.2.4. Latin America
    • 8.2.5. Middle East & Africa
  • 8.3. Market Attractiveness Analysis, by Region

9. North America Insulin Market Analysis and Forecast

  • 9.1. Introduction
    • 9.1.1. Key Findings
  • 9.2. Market Value Forecast, by Mode of Action, 2017-2031
    • 9.2.1. Rapid-acting
    • 9.2.2. Short-acting
    • 9.2.3. Intermediate-acting
    • 9.2.4. Premixed
    • 9.2.5. Long-acting
  • 9.3. Market Value Forecast, by Source, 2017-2031
    • 9.3.1. Modern Insulin
    • 9.3.2. Human Insulin
  • 9.4. Market Value Forecast, by Country, 2017-2031
    • 9.4.1. U.S.
    • 9.4.2. Canada
  • 9.5. Market Attractiveness Analysis
    • 9.5.1. By Mode of Action
    • 9.5.2. By Source
    • 9.5.3. By Country

10. Europe Insulin Market Analysis and Forecast

  • 10.1. Introduction
    • 10.1.1. Key Findings
  • 10.2. Market Value Forecast, by Mode of Action, 2017-2031
    • 10.2.1. Rapid-acting
    • 10.2.2. Short-acting
    • 10.2.3. Intermediate-acting
    • 10.2.4. Premixed
    • 10.2.5. Long-acting
  • 10.3. Market Value Forecast, by Source, 2017-2031
    • 10.3.1. Modern Insulin
    • 10.3.2. Human Insulin
  • 10.4. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 10.4.1. Germany
    • 10.4.2. U.K.
    • 10.4.3. France
    • 10.4.4. Italy
    • 10.4.5. Spain
    • 10.4.6. Rest of Europe
  • 10.5. Market Attractiveness Analysis
    • 10.5.1. By Mode of Action
    • 10.5.2. By Source
    • 10.5.3. By Country/Sub-region

11. Asia Pacific Insulin Market Analysis and Forecast

  • 11.1. Introduction
    • 11.1.1. Key Findings
  • 11.2. Market Value Forecast, by Mode of Action, 2017-2031
    • 11.2.1. Rapid-acting
    • 11.2.2. Short-acting
    • 11.2.3. Intermediate-acting
    • 11.2.4. Premixed
    • 11.2.5. Long-acting
  • 11.3. Market Value Forecast, by Source, 2017-2031
    • 11.3.1. Modern Insulin
    • 11.3.2. Human Insulin
  • 11.4. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 11.4.1. China
    • 11.4.2. Japan
    • 11.4.3. India
    • 11.4.4. Australia & New Zealand
    • 11.4.5. Rest of Asia Pacific
  • 11.5. Market Attractiveness Analysis
    • 11.5.1. By Mode of Action
    • 11.5.2. By Source
    • 11.5.3. By Country/Sub-region

12. Latin America Insulin Market Analysis and Forecast

  • 12.1. Introduction
    • 12.1.1. Key Findings
  • 12.2. Market Value Forecast, by Mode of Action, 2017-2031
    • 12.2.1. Rapid-acting
    • 12.2.2. Short-acting
    • 12.2.3. Intermediate-acting
    • 12.2.4. Premixed
    • 12.2.5. Long-acting
  • 12.3. Market Value Forecast, by Source, 2017-2031
    • 12.3.1. Modern Insulin
    • 12.3.2. Human Insulin
  • 12.4. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 12.4.1. Brazil
    • 12.4.2. Mexico
    • 12.4.3. Rest of Latin America
  • 12.5. Market Attractiveness Analysis
    • 12.5.1. By Mode of Action
    • 12.5.2. By Source
    • 12.5.3. By Country/Sub-region

13. Middle East & Africa Insulin Market Analysis and Forecast

  • 13.1. Introduction
    • 13.1.1. Key Findings
  • 13.2. Market Value Forecast, by Mode of Action, 2017-2031
    • 13.2.1. Rapid-acting
    • 13.2.2. Short-acting
    • 13.2.3. Intermediate-acting
    • 13.2.4. Premixed
    • 13.2.5. Long-acting
  • 13.3. Market Value Forecast, by Source, 2017-2031
    • 13.3.1. Modern Insulin
    • 13.3.2. Human Insulin
    • 13.3.3. Infection Treatment
    • 13.3.4. Gas Embolism
  • 13.4. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 13.4.1. GCC Countries
    • 13.4.2. South Africa
    • 13.4.3. Rest of Middle East & Africa
  • 13.5. Market Attractiveness Analysis
    • 13.5.1. By Mode of Action
    • 13.5.2. By Source
    • 13.5.3. By Country

14. Competition Landscape

  • 14.1. Market Player - Competition Matrix (by tier and size of companies)
  • 14.2. Market Share Analysis, by Company, 2021
  • 14.3. Company Profiles
    • 14.3.1. Shanghai Fosun Pharmaceutical Co., Ltd.
      • 14.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.1.2. Financial Analysis
      • 14.3.1.3. Growth Strategies
      • 14.3.1.4. SWOT Analysis
    • 14.3.2. Tonghua Dongbao
      • 14.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.2.2. Financial Analysis
      • 14.3.2.3. Growth Strategies
      • 14.3.2.4. SWOT Analysis
    • 14.3.3. Eli Lilly and Company
      • 14.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.3.2. Financial Analysis
      • 14.3.3.3. Growth Strategies
      • 14.3.3.4. SWOT Analysis
    • 14.3.4. Sanofi
      • 14.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.4.2. Financial Analysis
      • 14.3.4.3. Growth Strategies
      • 14.3.4.4. SWOT Analysis
    • 14.3.5. Novo Nordisk A/S
      • 14.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.5.2. Financial Analysis
      • 14.3.5.3. Growth Strategies
      • 14.3.5.4. SWOT Analysis
    • 14.3.6. Julphar
      • 14.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.6.2. Financial Analysis
      • 14.3.6.3. Growth Strategies
      • 14.3.6.4. SWOT Analysis
    • 14.3.7. Biocon Ltd.
      • 14.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.7.2. Financial Analysis
      • 14.3.7.3. Growth Strategies
      • 14.3.7.4. SWOT Analysis
    • 14.3.8. Becton, Dickinson and Company
      • 14.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.8.2. Financial Analysis
      • 14.3.8.3. Growth Strategies
      • 14.3.8.4. SWOT Analysis
    • 14.3.9. Ypsomed AG
      • 14.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.9.2. Financial Analysis
      • 14.3.9.3. Growth Strategies
      • 14.3.9.4. SWOT Analysis
    • 14.3.10. Biodel Inc.
      • 14.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.10.2. Financial Analysis
      • 14.3.10.3. Growth Strategies
      • 14.3.10.4. SWOT Analysis
    • 14.3.11. B. Braun Melsungen AG
      • 14.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.11.2. Financial Analysis
      • 14.3.11.3. Growth Strategies
      • 14.3.11.4. SWOT Analysis

List of Tables

  • Table 1: Market Snapshot: Global Insulin Market
  • Table 2: Global Prevalence of Diabetes, by Type
  • Table 3: Global Insulin Market Revenue (US$ Mn), by Mode of Action, 2017-2031
  • Table 4: Global Insulin Market Revenue (US$ Mn), by Source, 2017-2031
  • Table 5: Global Insulin Market Revenue (US$ Mn), by Region, 2017-2031
  • Table 6: North America Insulin Market Revenue (US$ Mn), by Mode of Action, 2017-2031
  • Table 7: Europe Insulin Market Revenue (US$ Mn), by Mode of Action, 2017-2031
  • Table 8: Asia Pacific Insulin Market Revenue (US$ Mn), by Mode of Action, 2017-2031
  • Table 9: Latin America Insulin Market Revenue (US$ Mn), by Mode of Action, 2017-2031
  • Table 10: Middle East & Africa Insulin Market Revenue (US$ Mn), by Mode of Action, 2017-2031

List of Figures

  • Figure 1: Insulin: Market Segmentation
  • Figure 2: Global Insulin Market Revenue (US$ Mn), by Mode of Action, 2021
  • Figure 3: China Insulin Market Revenue (US$ Mn), by Mode of Action, 2021
  • Figure 4: Value Chain: Global Insulin Market
  • Figure 5: Porter's Five Forces Analysis: Global Insulin Market
  • Figure 6: Market Attractiveness Analysis: Global Insulin Market, by Mode of Action
  • Figure 7: Comparative Analysis: Global Insulin Market Revenue (US$ Mn), by Mode of Action 2021 & 2031
  • Figure 8: Global Short-Acting Insulin Market Revenue (US$ Mn), 2017 - 2031
  • Figure 9: Global Short-Acting Insulin Market Volume (tMU), 2017 - 2031
  • Figure 10: Global Rapid-Acting Insulin Market Revenue (US$ Mn), 2017 - 2031
  • Figure 11: Global Rapid-Acting Insulin Market Volume (tMU), 2017 - 2031
  • Figure 12: Global Afrezza Market Revenue (US$ Mn), 2017 - 2031
  • Figure 13: Global NN1218 Market Revenue (US$ Mn), 2017 - 2031
  • Figure 14: Global Long-Acting Insulin Market Revenue, 2017 - 2031
  • Figure 15: Global Long-Acting Insulin Market Volume (tMU), 2017 - 2031
  • Figure 16: Global LY2605541 Market Revenue (US$ Mn), 2017 - 2031
  • Figure 17: Global LY2963016 Market Revenue (US$ Mn), 2017 - 2031
  • Figure 18: Global MK-1293 Market Revenue (US$ Mn), 2017 - 2031
  • Figure 19: Global U-300 Market Revenue (US$ Mn), 2017 - 2031
  • Figure 20: Global IDegLira Market Revenue (US$ Mn), 2017 - 2031
  • Figure 21: Global Intermediate-acting Insulin Market Revenue (US$ Mn), 2017 - 2031
  • Figure 22: Global Intermediate-acting Insulin Market Volume (tMU), 2017 - 2031
  • Figure 23: Global Premixed Market Revenue (US$ Mn), 2017 - 2031
  • Figure 24: Global Premixed Insulin Market Volume (tMU), 2017 - 2031
  • Figure 25: Breakdown of insulin-dependent population in China (2009)
  • Figure 26: China Short-Acting Insulin Market Revenue (US$ Mn), 2017 - 2031
  • Figure 27: China Short-Acting Insulin Market Volume (tMU), 2017 - 2031
  • Figure 28: China Rapid-Acting Insulin Market Revenue (US$ Mn), 2017 - 2031
  • Figure 29: China Rapid-Acting Insulin Market Volume (tMU), 2017 - 2031
  • Figure 30: China Long-Acting Insulin Market Revenue (US$ Mn), 2017 - 2031
  • Figure 31: China Long-Acting Insulin Market Volume (tMU), 2017 - 2031
  • Figure 32: China Intermediate-Acting Insulin Market Revenue (US$ Mn), 2017 - 2031
  • Figure 33: China Intermediate-Acting Insulin Market Volume (tMU), 2017 - 2031
  • Figure 34: China Premixed Insulin Market Revenue (US$ Mn), 2017 - 2031
  • Figure 35: China Premixed Insulin Market Volume (tMU), 2017 - 2031
  • Figure 36: Global Human Insulin Market Revenue (US$ Mn), 2017 - 2031
  • Figure 37: Global Human Insulin Market Volume (tMU), 2017 - 2031
  • Figure 38: Global Modern Insulin Market Revenue (US$ Mn), 2017 - 2031
  • Figure 39: Global Modern Insulin Market Volume (tMU), 2017 - 2031
  • Figure 40: China Human Insulin Market Revenue (US$ Mn), 2017 - 2031
  • Figure 41: China Human Insulin Market Volume (tMU), 2017 - 2031
  • Figure 42: China Modern Insulin Market Revenue (US$ Mn), 2017 - 2031
  • Figure 43: China Modern Insulin Market Volume (tMU), 2017 - 2031
  • Figure 44: Global Insulin Market Share Analysis, by Key Players, 2021 (%)
  • Figure 45: Global Insulin Market Share Analysis, by Key Players, 2021 (%)
  • Figure 46: Eli Lilly and Company: Annual Revenue (US$ Mn), 2017 - 2031
  • Figure 47: Novo Nordisk A/S.: Annual Revenue (US$ Mn), 2017 - 2031
  • Figure 48: Sanofi: Annual Revenue (US$ Mn), 2017 - 2031
  • Figure 49: Shanghai Fosun Pharmaceutical Co., Ltd.: Annual Revenue (US$ Mn), 2017 - 2031